China’s biopharma sector ‘in prime position to challenge US leadership’

China’s biopharmaceutical sector is said to have entered an “innovation 2.0” phase as it moves to a commercialisation mindset that could see it sideline global competitors and outpace the US – despite restrictive trade policies. According to a new report on mainland Chinese biopharmaceutical innovation by analytics company Clarivate, China has matured from a phase of rapid expansion to an “innovation 2.0” phase of quality-focused development. “This transition represents a fundamental shift in priorities: from speed to quality, from chasing market trends to building sustainable competitive advantages, and from capital-driven growth to value-driven development,” according to the report published on…